Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Research groups

Sophie Morgan

Postdoctoral Researcher

The presence of proteinaceous inclusions composed of abnormal filamentous assemblies within neurons and glia characterises most neurodegenerative diseases. Alpha-synuclein filaments define a group of neurodegenerative diseases termed synucleinopathies, the most prevalent being Parkinson’s disease. Understanding how alpha-synuclein aggregates and the cellular processes that influence alpha-synuclein accumulation is crucial to understanding synucleinopathies.

I am a postdoctoral researcher with an expertise in alpha-synuclein aggregation; I obtained my PhD in 2017 from the University of Cambridge with Prof. Michel Goedert. Now, as part of the Alzheimer’s Research UK Oxford Drug Discovery Institute and in collaboration with the Department of Physiology, Anatomy and Genetics, I am designing drug screening assays for potential targets in Parkinson’s disease.